John S Lazo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2703717/publications.pdf

Version: 2024-02-01

79 papers	3,020 citations	159585 30 h-index	168389 53 g-index
159 all docs	159 docs citations	159 times ranked	3810 citing authors

#	Article	IF	Citations
1	Transcriptome and Translatome Regulation of Pathogenesis in Alzheimerâ€™s Disease Model Mice. Journal of Alzheimer's Disease, 2022, 86, 365-386.	2.6	3
2	Combination of Subtherapeutic Doses of Tretazicar and Liposomal Amphotericin B Suppresses and Cures Leishmania major-Induced Cutaneous Lesions in Murine Models. ACS Infectious Diseases, 2021, 7, 506-517.	3.8	5
3	Single intratracheal exposure to SARSâ€CoVâ€2 S1 spike protein induces acute lung injury in K18â€hACE2 transgenic mice. FASEB Journal, 2021, 35, .	0.5	2
4	Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer. Biomolecules, 2021, 11, 969.	4.0	5
5	The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Îš18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L477-L484.	2.9	82
6	Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway. Bioorganic and Medicinal Chemistry Letters, 2021, 46, 128167.	2.2	3
7	The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons. Assay and Drug Development Technologies, 2020, 18, 97-103.	1.2	2
8	Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin. Molecular Pharmacology, 2020, 98, 648-657.	2.3	7
9	A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a senescence-associated secretory phenotype. Neurobiology of Aging, 2020, 90, 125-134.	3.1	11
10	Effect of Pharmacological Inhibition of the Catalytic Activity of Phosphatases of Regenerating Liver in Early T Cell Receptor Signaling Dynamics and IL-2 Production. International Journal of Molecular Sciences, 2020, 21, 2530.	4.1	5
11	Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2008-2015.	2.2	12
12	The hubris and humility of cancer pharmacology in the post immunoâ€oncology era. Pharmacology Research and Perspectives, 2019, 7, e00527.	2.4	3
13	In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors. Organic and Biomolecular Chemistry, 2019, 17, 2448-2466.	2.8	13
14	Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 652-662.	2.5	11
15	Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimerâ€™s Disease and Brain Insulin Resistance, and Its Relation to Cancer. Journal of Alzheimer's Disease, 2019, 67, 1-11.	2.6	20
16	The Mechanism of Inhibition of the Undrugged Oncogenic Phosphatase PTP4A3 by a Novel Small Molecule JMSâ€053. FASEB Journal, 2019, 33, 674.14.	0.5	0
17	Next Generation Potent Cellâ€active Inhibitors of the Oncogenic PTP4A3 Phosphatase. FASEB Journal, 2019, 33, 674.11.	0.5	0
18	Refining Radiation for the Next Century. Molecular Cancer Therapeutics, 2018, 17, 332-335.	4.1	0

#	Article	IF	Citations
19	Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis. Neuropharmacology, 2018, 136, 192-195.	4.1	31
20	Small molecule targeting of PTPs in cancer. International Journal of Biochemistry and Cell Biology, 2018, 96, 171-181.	2.8	32
21	High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods in Molecular Biology, 2018, 1683, 229-244.	0.9	5
22	A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion. FASEB Journal, 2018, 32, 5661-5673.	0.5	12
23	Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches. F1000Research, 2018, 7, 308.	1.6	3
24	Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget, 2018, 9, 8223-8240.	1.8	27
25	New Approaches to Difficult Drug Targets: The Phosphatase Story. SLAS Discovery, 2017, 22, 1071-1083.	2.7	26
26	Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells. Assay and Drug Development Technologies, 2016, 14, 226-239.	1.2	26
27	Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3581-3585.	2.2	27
28	Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor. Organic and Biomolecular Chemistry, 2016, 14, 6398-6402.	2.8	37
29	Drugging Undruggable Molecular Cancer Targets. Annual Review of Pharmacology and Toxicology, 2016, 56, 23-40.	9.4	170
30	Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. Bioorganic and Medicinal Chemistry, 2015, 23, 2810-2818.	3.0	33
31	HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Assay and Drug Development Technologies, 2015, 13, 356-376.	1.2	24
32	Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents. Expert Opinion on Investigational Drugs, 2014, 23, 661-673.	4.1	15
33	2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5081-5085.	2.2	15
34	Protein-tyrosine Phosphatase 4A3 (PTP4A3) Promotes Vascular Endothelial Growth Factor Signaling and Enables Endothelial Cell Motility. Journal of Biological Chemistry, 2014, 289, 5904-5913.	3.4	39
35	Deletion of Ptp4a3 reduces clonogenicity and tumor-initiation ability of colitis-associated cancer cells in mice. Stem Cell Research, 2014, 13, 164-171.	0.7	15
36	Pharmacologic Profiling of Phosphoinositide 3-Kinase Inhibitors as Mitigators of Ionizing Radiationâ€"Induced Cell Death. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 669-680.	2.5	13

#	Article	IF	Citations
37	Targeted Deletion of the Metastasis-Associated Phosphatase Ptp4a3 (PRL-3) Suppresses Murine Colon Cancer. PLoS ONE, 2013, 8, e58300.	2.5	59
38	Disruption of the PI3K axis abrogates ionizing radiationâ€induced cell death. FASEB Journal, 2013, 27, 1181.7.	0.5	0
39	Identifying a Resistance Determinant for the Antimitotic Natural Products Disorazole C₁ and A₁. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 906-911.	2.5	9
40	Phosphatase of Regenerating Liver-1 Promotes Cell Migration and Invasion and Regulates Filamentous Actin Dynamics. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 627-633.	2.5	38
41	Molecular Biology and Anticancer Drug Discovery. Progress in Molecular Biology and Translational Science, 2010, 95, 9-29.	1.7	4
42	Profiling the NIH Small Molecule Repository for Compounds That Generate H₂O₂by Redox Cycling in Reducing Environments. Assay and Drug Development Technologies, 2010, 8, 152-174.	1.2	93
43	Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen. PLoS Neglected Tropical Diseases, 2009, 3, e540.	3.0	53
44	Cdc25B Dual-Specificity Phosphatase Inhibitors Identified in a High-Throughput Screen of the NIH Compound Library. Assay and Drug Development Technologies, 2009, 7, 250-265.	1.2	35
45	Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nature Chemical Biology, 2009, 5, 680-687.	8.0	221
46	Phosphatases as targets for cancer treatment. Current Opinion in Investigational Drugs, 2009, 10, 1297-304.	2.3	11
47	Development of a 384-Well Colorimetric Assay to Quantify Hydrogen Peroxide Generated by the Redox Cycling of Compounds in the Presence of Reducing Agents. Assay and Drug Development Technologies, 2008, 6, 505-518.	1.2	106
48	A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Molecular Cancer Therapeutics, 2008, 7, 330-340.	4.1	54
49	Is Cdc25 a Druggable Target?. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 837-842.	1.7	26
50	Nitrosative Stress Triggers Inhibition of DNA Synthesis and Translational Suppression of Positive Cell Cycle Regulators. FASEB Journal, 2008, 22, 835.1.	0.5	0
51	Druggable Genome siRNA-Screening Identifies Glybenclamide as a Radioprotector against Total Body Irradiation. Blood, 2008, 112, 504-504.	1.4	4
52	Building a Pharmacological Lexicon: Small Molecule Discovery in Academia. Molecular Pharmacology, 2007, 72, 1-7.	2.3	50
53	Development and Implementation of a 384-Well Homogeneous Fluorescence Intensity High-Throughput Screening Assay to Identify Mitogen-Activated Protein Kinase Phosphatase-1 Dual-Specificity Protein Phosphatase Inhibitors. Assay and Drug Development Technologies, 2007, 5, 319-332.	1.2	36
54	Structurally Unique Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1 Identified in a Pyrrole Carboxamide Library. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 940-947.	2.5	24

#	Article	IF	Citations
55	Independent Mechanistic Inhibition of Cdc25 Phosphatases by a Natural Product Caulibugulone. Molecular Pharmacology, 2007, 71, 184-192.	2.3	43
56	Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nature Protocols, 2007, 2, 1134-1144.	12.0	61
57	Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC) Tj ETQq1 1 0.784314 rgBT /Ov	1.1	15
58	The Benzo[c]phenanthridine Alkaloid, Sanguinarine, Is a Selective, Cell-active Inhibitor of Mitogen-activated Protein Kinase Phosphatase-1. Journal of Biological Chemistry, 2005, 280, 19078-19086.	3.4	172
59	Redox Regulation of Cdc25B by Cell-Active Quinolinediones. Molecular Pharmacology, 2005, 68, 1810-1820.	2.3	81
60	Live Long and Prosper: Fig. 1.. Molecular Pharmacology, 2005, 68, 1193-1195.	2.3	0
61	Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase. Molecular Pharmacology, 2004, 66, 824-833.	2.3	71
62	Synthesis and biological evaluation of caulibugulones Aâ€“E. Organic and Biomolecular Chemistry, 2004, 2, 2173-2174.	2.8	35
63	Desperately Seeking Genotype-Selective Anticancer Agents. Chemistry and Biology, 2003, 10, 477-478.	6.0	0
64	Cell-Active Dual Specificity Phosphatase Inhibitors Identified by High-Content Screening. Chemistry and Biology, 2003, 10, 733-742.	6.0	61
65	Sleuthful Pharmacology. Molecular Pharmacology, 2003, 64, 199-201.	2.3	4
66	Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors.. Molecular Pharmacology, 2002, 61, 720-728.	2.3	175
67	Changes and challenges â€” the world post-Gleevecâ„¢ (GlivecÂ®). Current Opinion in Pharmacology, 2002, 2, 357-360.	3.5	2
68	Dual-specificity phosphatases as targets for antineoplastic agents. Nature Reviews Drug Discovery, 2002, 1, 961-976.	46.4	132
69	Apolipoprotein A-I Directly Interacts with Amyloid Precursor Protein and Inhibits Aî² Aggregation and Toxicity. Biochemistry, 2001, 40, 3553-3560.	2.5	120
70	Discovery and Biological Evaluation of a New Family of Potent Inhibitors of the Dual Specificity Protein Phosphatase Cdc25. Journal of Medicinal Chemistry, 2001, 44, 4042-4049.	6.4	192
71	Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors. , 2000, 71, 58-70.		8
72	Small molecule inhibitors of dual specificity protein phosphatases. Oncogene, 2000, 19, 6607-6612.	5.9	53

#	Article	IF	Citations
73	Human bleomycin hydrolase regulates the secretion of amyloid precursor protein. FASEB Journal, 2000, 14, 1837-1847.	0.5	40
74	Cell cycle dependent subcellular distribution of Cdc25B subtypes. Oncogene, 1999, 18, 2770-2776.	5.9	20
75	Dual G1 and G2/M phase inhibition by SC-Î±Î±Î´9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene, 1999, 18, 6989-6996.	5.9	22
76	Essential Binding and Functional Domains of Human Bleomycin Hydrolaseâ€. Biochemistry, 1998, 37, 2282-2290.	2.5	32
77	A Targeted Library of Small-Molecule, Tyrosine, and Dual-Specificity Phosphatase Inhibitors Derived from a Rational Core Design and Random Side Chain Variationâ€. Biochemistry, 1997, 36, 15965-15974.	2.5	76
78	Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel. Cancer Chemotherapy and Pharmacology, 1997, 41, 61-68.	2.3	40
79	Gene Therapy and Endothelial Cell Targeting for Cancer. Annals of the New York Academy of Sciences, 1994, 716, 257-264.	3.8	7